Turkish pharma sector doubles to $8.4B; J&J pulls potentially flammable bone putty;

 @FiercePharma: Check out the soon-to-be-launched Facebook game from Boehringer, if you haven't already. More | Follow @FiercePharma

> Turkey's pharma sector has doubled over the past 10 years, to a market volume of 15 billion Turkish liras, or about $8.4 billion. Report

> Johnson & Johnson ($JNJ) pulled certain lots of its Synthes unit's Hemostatic Bone Putty because of the risk that it might catch fire during surgery. Report

> Italian drugmaker Angelini sued a unit of Actavis for patent infringement over the Swiss generics maker's plans to sell a copy of the antidepressant Oleptro. Report

> Spectrum Pharmaceuticals increased discounting on its cancer drug Fusilev last quarter, boosting sales, but at lower prices. Report

> India's Wockhardt won tentative FDA approval for its generic version of the antipsychotic drug Geodon. Report

> FDA warned that Reumofan dietary supplements, marketed as remedies for arthritis and muscle pain, actually contain prescription drugs that could interfere with other meds, causing severe side effects. Report

Medical Device News

@FierceMedDev: Siemens buys an ultrasound imaging startup - Penrith Corp. More | Follow @FierceMedDev

 @MarkHFierce: ForSight Vision 5., a opthalmology device startup, raised $8 million. Via MedCity News. More | Follow @MarkHFierce

 @DamianFierce: Another recall from Covidien, this time over its Duet tissue-reinforcement device, tied to three deaths. More | Follow @DamianFierce

> Medtronic's Ishrak confident in face of Medicare, device tax and slow CRM market. Article

> J&J's Synthes recalls bone putty over fire risk. News

> Device tax could curtail hip and knee replacements. Item

Biotech News

 @FierceBiotech: Boehringer sets Sept. launch date for pharma's first social game on Facebook. Article | Follow @FierceBiotech

 @JohnCFierce: SEC charges biotech exec with insider trading - first Bristol-Myers Squibb, now Array. Another one of these and I'm calling it a trend. More | Follow @JohnCFierce

 @RyanMFierce: Merck's Varivax slashes U.S. chickenpox cases. More | Follow @RyanMFierce

> Analysts: Roche's armed antibody will help drive breast cancer drug sales. Story

> Gilead writes off $11M gamble after PAH drug flunks PhII. News

> Analysts show why orphan drug development is going gangbusters. Report

Biomarkers News

> Gene signature picks out radiation-sensitive cancers. Story

> Blood biomarkers could pinpoint common kidney disease. More

> It's all relative: Protein marks lower dementia risk in siblings. Item

> Biomarker signatures tag liver transplant failure. Article

Drug Delivery News

> Tobacco money funds NanoJacket cancer drug delivery. News

> Ocular Therapeutix eyes punctal delivery in Phase II. Story

> Protein capsules fight a toothy battle. Article

> DNA origami delivers doxorubicin, downs resistance. More

And Finally... An NIH-supported trial will test whether fecal transplant can treat relapsing C. difficile infection. Release

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.